2026-10-30 15:46:00 UTC#546742duplicateconfirmednews
Ultragenyx receives conditional U.K. marketing authorization for Dojolvi
seeking alphaimportance 0.30trust 0.70Ultragenyx Pharmaceutical Inc. +0.50Dojolvi +0.50United Kingdom 0
RARE stock news
RARE stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-19 13:22:11 UTC#480746newconfirmednews
Ultragenyx settles Dojolvi patent litigation with Navinta, allowing generic entry in 2033
2026-10-15 21:40:00 UTC#468631newconfirmednews
UBS initiates Ultragenyx Pharmaceutical (RARE) at Neutral with $16.00 price target
2026-10-14 14:32:00 UTC#459778duplicateconfirmednews
Ultragenyx Pharmaceutical confirms $203 million sale of Fayuvi priority review voucher
dow_jonesimportance 0.30trust 0.80Ultragenyx Pharmaceutical, Inc. +0.40Fayuvi +0.30Food and Drug Administration +0.20+1 entities
2026-10-14 14:17:00 UTC#459698duplicateconfirmednews
Ultragenyx Pharmaceutical confirms $203M sale of Fayuvi priority review voucher
dow_jonesimportance 0.30trust 0.90Ultragenyx Pharmaceutical Inc. +0.40Food and Drug Administration +0.20Fayuvi +0.30+1 entities
2026-10-14 12:30:00 UTC#458995duplicateconfirmednews
Ultragenyx Pharmaceutical Inc. (RARE) confirms $203M sale of Rare Pediatric Disease Priority Review Voucher
2026-10-14 12:30:00 UTC#458994newconfirmedpress release
Ultragenyx to sell Rare Pediatric Disease Priority Review Voucher for $203 million
globenewswireimportance 0.60trust 1.00Ultragenyx Pharmaceutical Inc. +0.60U.S. Food and Drug Administration +0.20FAYUVI +0.40+1 entities
2026-10-07 14:09:24 UTC#426221newconfirmednews
Ultragenyx Pharmaceutical to sell FDA priority review voucher for $210 million
seeking alphaimportance 0.50trust 0.70Ultragenyx Pharmaceutical Inc. +0.40Food and Drug Administration +0.20
2026-10-02 06:00:00 UTC#403442duplicateconfirmednews
Ultragenyx EMA validates MAA for MPS IIIA gene therapy rebisufligene etisparvovec
globenewswireimportance 0.40trust 1.00Ultragenyx Pharmaceutical Inc. +0.40European Medicines Agency +0.30rebisufligene etisparvovec +0.40+1 entities
2026-10-02 06:00:00 UTC#403440newconfirmednews
Ultragenyx EMA validation of UX111 MAA for MPS IIIA treatment begins formal EU review process
tradingviewimportance 0.50trust 0.80Ultragenyx Pharmaceutical Inc. +0.40European Medicines Agency +0.30rebisufligene etisparvovec +0.40+1 entities
2026-09-29 13:05:19 UTC#384415newconfirmedpress release
Tactical Resources Corp. (TREO) appoints Pecos River Commission Chairman P. Lourcey Sams as Special Advisor
financial postimportance 0.30trust 0.90Tactical Resources Corp. +0.20P. Lourcey Sams +0.20Pecos River Commission 0
2026-09-22 13:00:00 UTC#348964newforecastnews
Global Rare Earth Elements Market Forecast to Reach $10.44 Billion by 2030, 11.1% CAGR
pr_newswireimportance 0.30trust 0.40Tactical Resources Corp. +0.20USA Rare Earth, Inc. +0.20MP Materials Corp. +0.20+2 entities
2026-09-22 12:45:04 UTC#348774newconfirmedpress release
Tactical Resources (TREO) outlines development roadmap for Peak rare earth project in Texas
2026-09-21 16:41:00 UTC#344021newconfirmednews
Evercore ISI Group raises Ultragenyx Pharmaceutical (RARE) price target to $18 from $16
2026-09-18 16:41:00 UTC#334780newconfirmednews
Morgan Stanley raises Ultragenyx Pharmaceutical price target to $20.00 from $18.00
2026-09-18 14:26:00 UTC#334065newconfirmednews
Citigroup maintains Buy rating on Ultragenyx Pharmaceutical, raises price target to $32 from $31
2026-09-18 09:41:18 UTC#332401newconfirmednews
Cantor Fitzgerald maintains Overweight rating on Ultragenyx Pharmaceutical, sets $39 price target
tradingviewimportance 0.40trust 0.60Cantor Fitzgerald, L.P. +0.30Ultragenyx Pharmaceutical Inc. +0.40
2026-09-18 06:49:34 UTC#331997duplicateconfirmednews
Ultragenyx Pharmaceutical shares rise 12.6% following FDA approval of Fayuvi gene therapy
zerodha pulseimportance 0.30trust 0.60Ultragenyx Pharmaceutical Inc. +0.50Fayuvi +0.60Food and Drug Administration +0.50
2026-09-17 21:07:00 UTC#330068duplicateconfirmednews
FDA approves Ultragenyx Pharmaceutical gene therapy Fayuvi for Sanfilippo syndrome type A
dow_jonesimportance 0.30trust 0.90Ultragenyx Pharmaceutical, Inc. +0.80Food and Drug Administration +0.50Fayuvi +0.80+1 entities
2026-09-17 20:08:00 UTC#329758duplicateconfirmednews
Ultragenyx Pharmaceutical shares rise following FDA approval of Fayuvi for Sanfilippo syndrome type A
dow_jonesimportance 0.40trust 0.90Ultragenyx Pharmaceutical, Inc. +0.80U.S. Food and Drug Administration +0.50Fayuvi +0.80+1 entities